Literature DB >> 3609119

Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

L J Schaaf, B R Dobbs, I R Edwards, D G Perrier.   

Abstract

The nonlinear disposition kinetics of 5-fluorouracil (5-FU) were investigated in 6 patients with colorectal carcinoma. Each patient randomly received two single, intravenous doses of 5-FU (7.5 and 15 mg/kg) on separate days. Venous blood and urine samples were collected just prior to and for 5 h after drug administration. In addition to the kinetic studies, the in vitro whole blood/plasma concentration ratio and stability of 5-FU at 37 degrees C were determined in whole blood from normal volunteers and from 5 patients with colorectal carcinoma. A disproportionate increase in area under the curve and corresponding decrease in total body clearance with increasing dose was observed suggesting dose-dependent behavior of 5-FU. Doubling the dose was accompanied by a 36% decrease in nonrenal clearance but no apparent change in renal clearance. Therefore, the mechanism for dose-dependent elimination appears to be primarily associated with nonrenal processes. The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12.3 versus 6.2 min). The log-linear decline in plasma concentrations and increase in half-life with dose suggest the potential role of product-inhibition as an explanation for the observed nonlinearity in 5-FU elimination. The present study demonstrates that 5-FU degrades when incubated in whole blood. This most likely reflects metabolism in red blood cells or other blood-formed elements since 5-FU was stable in plasma. Although degradation in whole blood occurs, the estimated whole blood clearance does not contribute significantly to the observed total body clearance value. The findings suggest the possibility of pulmonary clearance of 5-FU.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609119     DOI: 10.1007/bf00543978

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

2.  Kinetics and mechanisms of drug action of microorganisms XXIII: microbial kinetic assay for fluorouracil in biological fluids and its application to human pharmacokinetics.

Authors:  E R Garrett; G H Hurst; J R Green
Journal:  J Pharm Sci       Date:  1977-10       Impact factor: 3.534

3.  Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.

Authors:  B Gustavsson; L Hafström
Journal:  Acta Chir Scand Suppl       Date:  1981

Review 4.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

5.  Pharmacokinetics of 5-fluorouracil : impact of the measurement of the 5,6-dihydrofluorouracil.

Authors:  C Aubert; J P Cano; J P Rigault; J F Seitz; Y Carcassonne
Journal:  Bull Cancer       Date:  1981       Impact factor: 1.276

6.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva.

Authors:  L A Celio; G J DiGregorio; E Ruch; J Pace; A J Piraino
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism.

Authors:  E Cadman; R Heimer; L Davis
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

9.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

10.  Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography mass spectrometry.

Authors:  C Aubert; J P Sommadossi; P Coassolo; J P Cano; J P Rigault
Journal:  Biomed Mass Spectrom       Date:  1982-08
View more
  14 in total

1.  Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.

Authors:  Nitin Kaila; Robert J Straka; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

2.  The in vitro stability of doxifluridine in whole blood and plasma.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.

Authors:  C Coustère; F Mentré; J P Sommadossi; R B Diasio; J L Steimer
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 5.  Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.

Authors:  J Levin; J Hohneker
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

6.  Relationships between body composition parameters and fluorouracil pharmacokinetics.

Authors:  Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

7.  Pharmacokinetic analysis of doxifluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs.

Authors:  In-Hwan Baek; Byung-Yo Lee; Min-Soo Kim; Kwang-Il Kwon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-07       Impact factor: 2.441

8.  5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.

Authors:  D P Baccanari; S T Davis; V C Knick; T Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

9.  Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system.

Authors:  E C Spoelstra; H M Pinedo; H Dekker; G J Peters; J Lankelma
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.